- Sputnik International, 1920
World
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

Johnson & Johnson Files for Emergency Use Approval of COVID Vaccine in S. Africa, Reports Suggest

© REUTERS / Phill Magakoe/Pool Healthcare workers chat at a temporary ward set up during the coronavirus disease (COVID-19) outbreak, at Steve Biko Academic Hospital in Pretoria, South Africa, January 19, 2021
Healthcare workers chat at a temporary ward set up during the coronavirus disease (COVID-19) outbreak, at Steve Biko Academic Hospital in Pretoria, South Africa, January 19, 2021 - Sputnik International, 1920, 08.02.2021
Subscribe
MOSCOW (Sputnik) - The United States' Johnson & Johnson has requested South Africa's regulator for the emergency use authorization of its single-shot vaccine against the coronavirus, the African country's eNCA broadcaster reported on Monday as Johannesburg temporarily suspended its rollout of the AstraZeneca vaccine.

According to the broadcaster, the use of the vaccine may be approved in the next few days.

On Sunday, Health Minister Zweli Mkhize said that the government was putting vaccination with the AstraZeneca vaccine on hold over its reported ineffectiveness against the new coronavirus strain originating in South Africa.

In this Aug. 14, 2020, file photo, laboratory technicians work at the mAbxience biopharmaceutical company on an experimental coronavirus vaccine developed by Oxford University and the laboratory AstraZeneca in Garin, Argentina. - Sputnik International, 1920, 08.02.2021
World
South African Opposition Slams Gov't Vaccination Drive Amid Halted AstraZeneca Vaccine Rollout

Apart from the Johnson & Johnson vaccine, the government is now banking on the one by Pfizer/BioNTech. The national spokesman for the opposition Congress of the People, Dennis Bloem, described the situation as undermining trust in the vaccination campaign.

In late January, Johnson & Johnson said that its vaccine candidate was 66 percent effective in preventing moderate to severe cases of COVID-19. The vaccine proved to be 85 percent effective in preventing severe disease and provided complete protection against hospitalization and death 28 days after the shot. Last week, the company applied for the vaccine's authorization in the US.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала